Ambaw Bellete serves as President and Chief Operating Officer at CG Oncology, Inc., a clinical-stage biotechnology company pioneering innovative immunotherapies for bladder cancer. With over 25 years of experience in the biopharmaceutical industry, Bellete brings deep expertise in technical operations, manufacturing, and scaling therapies from early development to commercialization. He oversees all operational aspects of the company, including clinical development, manufacturing, supply chain, and regulatory affairs, driving the advancement of CG Oncology's lead candidate, cretostimogene grenadenorepvec, toward potential approval and market launch. Bellete's distinguished career includes senior leadership roles at several leading biotech firms. Prior to joining CG Oncology, he was Senior Vice President of Technical Operations at Seagen, where he led global manufacturing and supply chain operations during its $43 billion acquisition by Pfizer, ensuring seamless integration and production scale-up for antibody-drug conjugates. Previously, as Vice President of Manufacturing at Juno Therapeutics (acquired by Bristol Myers Squibb), he spearheaded the build-out of commercial-scale CAR-T cell therapy manufacturing, achieving key milestones in process optimization and regulatory submissions. His earlier positions at Genentech and Amgen honed his skills in bioprocessing, quality assurance, and CMC development for biologics and gene therapies. Under Bellete's leadership, CG Oncology has accelerated its clinical pipeline, including positive Phase 3 data from the BOND-003 trial, positioning the company for a potential BLA submission to the FDA. A proven operator in high-growth environments, Bellete's strategic vision and execution excellence have been instrumental in navigating complex acquisitions, regulatory landscapes, and operational challenges, earning him recognition as a key architect of successful biotech transitions.